What is TVTX's health score?

Travere Therapeutics, Inc. (TVTX) has a TradeApes health score of 39 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is TVTX's estimated fair value?

Based on our 5-year discounted cash flow model, Travere Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is TVTX undervalued or overvalued?

Our model currently rates TVTX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for TVTX... Refresh in a moment for the full analysis.

Travere Therapeutics, Inc. (TVTX)

Healthcare Inconclusive inconclusive weak

$45.81

Updated: 2026-06-06

TradeApes Score

Financial Strength

15 Stressed

Operating Trend

65 Healthy

Relative Value

30 Weak

Capital Allocation

40 Weak

Risk

50 Mixed

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.